ArticleProceedings of the National Academy of Sciences of the United States of America2008
The potential of desferrioxamine-gallium as an anti-Pseudomonas therapeutic agent.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
109 citing papers in PubMed, 251 citations in OpenAlex.
- A Siderophore-Antibiotic Heterodimer Imaging Agent EnablesJournal of medicinal chemistry · 2026Article
- TheEuropean journal of nuclear medicine and molecular imaging · 2026Observational
- Ferrichrome: bacterial function, synthetic mimics, and biomedical applications.Frontiers in microbiology · 2026Review
- Ferroptosis and iron-based therapies inVirulence · 2025Review
- Repurposing the Anticancer Drug KP46 to Beat the CRAB out of Resistance: Towards an Orally Active Ga-Based Antiplantonic and Antibiofilm Agent.Antibiotics (Basel, Switzerland) · 2025Article
- Deferoxamine addresses metabolic dysregulation and urinary tract infections in weight-associated gestational diabetes mellitus.European journal of medical research · 2025Article
- Fimsbactin Siderophores From a South African Marine Sponge Symbiont, Marinomonas sp. PE14-40.Microbial biotechnology · 2025Article
- Liquid Metal Gallium Pharmaceuticals.Theranostics · 2025Review
- Antimicrobial Activity of Gallium(III) Compounds: Pathogen-Dependent Targeting of Multiple Iron/Heme-Dependent Biological Processes.Current issues in molecular biology · 2024Review
- Strategies and materials for the prevention and treatment of biofilms.Materials today. Bio · 2023Review
- Development of Biocompatible GaAntibiotics (Basel, Switzerland) · 2023Article
- Dual-action gallium-flavonoid compounds for combatingRSC chemical biology · 2023Article
- Review
- Metallo-sideromycin as a dual functional complex for combating antimicrobial resistance.Nature communications · 2023Article
- Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process.Microbial biotechnology · 2023Review
- Siderophore conjugates to combat antibiotic-resistant bacteria.RSC medicinal chemistry · 2023Review
- Dual-Action Effect of Gallium and Silver Providing Osseointegration and Antibacterial Properties to Calcium Titanate Coatings on Porous Titanium Implants.International journal of molecular sciences · 2023Article
- A compensatory RNase E variation increases Iron Piracy and Virulence in multidrug-resistant Pseudomonas aeruginosa during Macrophage infection.PLoS pathogens · 2023Article
- Gallium-Based Liquid Metal Materials for Antimicrobial Applications.Bioengineering (Basel, Switzerland) · 2022Review
- Evolution of gallium applications in medicine and microbiology: a timeline.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022Review
49 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 2 countries.
Funding
Abstract
The opportunistic pathogen Pseudomonas aeruginosa causes infections that are difficult to treat by antibiotic therapy. This bacterium can cause biofilm infections where it shows tolerance to antibiotics. Here we report the novel use of a metallo-complex, desferrioxamine-gallium (DFO-Ga) that targets P. aeruginosa iron metabolism. This complex kills free-living bacteria and blocks biofilm formation. A combination of DFO-Ga and the anti-Pseudomonas antibiotic gentamicin caused massive killing of P. aeruginosa cells in mature biofilms. In a P. aeruginosa rabbit corneal infection, topical administration of DFO-Ga together with gentamicin decreased both infiltrate and final scar size by about 50% compared to topical application of gentamicin alone. The use of DFO-Ga as a Trojan horse delivery system that interferes with iron metabolism shows promise as a treatment for P. aeruginosa infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.